Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Prevalence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Under Treatment With Natalizumab (Tysabri): A Systematic Review and Meta-Analysis Publisher



Nasirzadeh A1 ; Jahanshahi R2 ; Ghajarzadeh M3, 4 ; Mohammadi A4 ; Sahraian MA3 ; Moghadasi AN3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Golestan University of Medical Sciences, Gorgan, Iran
  3. 3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Preventive Medicine Published:2023


Abstract

Background: To determine the pooled prevalence of cancer in subjects with multiple sclerosis (MS) who received Natalizumab. Methods: Two researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, google scholar, and gray literature including references of the included studies. The search strategy which was used in PubMed was (Disseminated SclerosisOR multiple sclerosisOR MSOR Acute Fulminating) AND (CancerOR Neoplasia*OR Neoplasm*OR Tumor*OR MalignancyOR Benign NeoplasmOR Malignant neoplasm) AND (TysabriOR AntegrenOR natalizumabOR Modifying Therapy). Results: We found 1,993 articles by literature search, and 1,573 studies remained after removing duplicate studies. For metaanalysis, we used the extracted data of eight studies. The pooled prevalence of cancer in patients who received Natalizumab was 2% (95%CI: 1-3%; I2: 99.4%, P < 0.001). The pooled prevalence of basal cell carcinoma in patients with cancer was 12% (95%CI: 5-20%; I2:50.3%, P = 0.13). Conclusions: The main finding of this systematic review and metaanalysis is that the pooled prevalence of cancer in subjects who suffer from MS and received natalizumab was 2%. © 2023 International Journal of Preventive Medicine.
Related Docs
1. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
2. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
3. Pyoderma Gangrenosum in a Patient With Multiple Sclerosis Under Natalizumab Treatment: A Case Report, BMC Neurology (2025)
4. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
5. The Prevalence of Inflammatory Bowel Disease (Ibd) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2023)
6. Incidence of Seroconversion and Sero-Reversion in Patients With Multiple Sclerosis (Ms) Who Had Been Treated With Natalizumab: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (3)
Amirreza Azimi (1)